After 3 days of BMS-690514 administration (30 mg kg−1 day−1), the proportion of tumour vessels seemed to be lesser than that in vehicle-treated controls and a qualitative reduction in CD34-positive vessel area was observed. Here, CD34 is linked to neoplasm.